Return to Listing

21 result(s) for Other Hematologic Malignancy

PI Name Protocol # Title
Stephen Spurgeon IRB00011311 A Phase 1/2 Proof-of-concept study of the combination of ACP-196 and ACP-319 in subjects with B-cell malignancies
Elie Traer STUDY00016142 A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation, With a Substudy in Subjects With Relapsed or Refractory Myelodysplastic Syndrome and a Substudy in Subjects With Advanced Hematologic Malignancies With Organ Impairment
Ronan Swords STUDY00016363 A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Richard Maziarz STUDY00016982 A Phase I Study of Donor BPX-501 T Cell Infusion for Adults with Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
Michael Heinrich STUDY00017155 A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Patients with Advanced Malignancies
Eva Medvedova STUDY00018388 [NCI CIRB] S1702, A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis
Ronan Swords STUDY00019142 An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post– ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor
Gabrielle Meyers STUDY00019856 A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF EQ001 IN SUBJECTS WITH NEWLY DIAGNOSED ACUTE GRAFT VERSUS HOST DISEASE
Richard Maziarz STUDY00019906 Long-Term Follow Up Protocol for Subjects Treated with Gene-Modified T Cells
Brandon Hayes-Lattin STUDY00019907 [NMDP - BMT CTN MOU] 1702: Clinical Transplant Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D)
Levanto Schachter STUDY00019914 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Jennifer Saultz STUDY00019915 [NMDP - BMT CTN MOU] CTN 1704: Composite Health Assessment Model for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation (CHARM)
Eneida Nemecek STUDY00020379 Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
Rachel Cook STUDY00020577 [Fred Hutch – SMART IRB]: Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality after Allogenic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients with Hematological Disease
Ronan Swords STUDY00020736 A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL)
Richard Maziarz STUDY00021119 An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients with Hematological Malignancies
Rachel Cook STUDY00021238 A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)
Levanto Schachter STUDY00021454 Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release.
Christopher Ryan STUDY00021677 [NCI CIRB] NCICOVID - NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Jennifer Saultz STUDY00021983 A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non–Hodgkin Lymphoma of B-Cell Origin
Joseph Shatzel STUDY00021999 Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080